Compare AU
Compare CURE vs. QUAL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck MSCI International Quality ETF (QUAL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | QUAL | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 79 | 1,334 |
Median incremental investment | $624.65 | $899.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,354.30 | $3,383.40 |
Average age group | > 35 | > 35 |
Key Summary
CURE | QUAL | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | QUAL's key objective is to invest in high-quality companies that have outperformed the market over the long term compared to global equity benchmarks. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Meta Platforms Inc Class A (5.50 %) Apple Inc (5.31 %) Microsoft Corp (4.74 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Information Technology (39.80 %) Communication Services (23.32 %) Financials (15.18 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (77.74 %) Switzerland (4.98 %) United Kingdom of Great Britain and Northern Ireland (4.22 %) |
Management fee | 0.45 % | 0.4 % |
Key Summary
CURE | QUAL | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MSCI World ex Australia Quality Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.4 % |
Price | $46.66 | $56.08 |
Size | $33.491 million | $7.317 billion |
10Y return | N/A | 212.08 % |
Annual distribution yield (5Y) | 4.24 % | 1.85 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 31/10/2014 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | QUAL | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 79 | 1,334 |
Median incremental investment | $624.65 | $899.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,354.30 | $3,383.40 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | QUAL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | QUAL |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |